Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 15/20 | 1.00 |
| ▸ | CTSD | P07339 | 13/20 | 1.00 |
| ▸ | REN | P00797 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536570 | 0.95 | BACE1 (0.91) | BACE1BACE2CTSDREN | |
| SCHEMBL3537614 | 0.93 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3541285 | 0.93 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3538753 | 0.92 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3539506 | 0.88 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3533042 | 0.87 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3540068 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3535860 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL3542070 | 0.86 | BACE1 (0.84) | BACE1BACE2CTSDREN | |
| SCHEMBL3535281 | 0.84 | BACE1 (1.00) | BACE1BACE2CTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756087-B1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH CORP (US) | 2009-10-07 | — | — | EP | claimed |
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-04-09 | — | — | US | claimed |
| US-7482349-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH (US) | 2009-01-27 | — | — | US | claimed |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | claimed |
| US-7700602-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1756087-B1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH CORP (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-7482349-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 158/4885 |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.